Hengrui Pharmaceuticals: A Fortress Innovation Platform, But RMB 50 Already Pays for the Upgrade

Company vertical history

Hengrui’s roots are older than its stock-market life. The company traces its origin to Lianyungang Pharmaceutical Factory, established in 1970, and the current listed company was incorporated in Lianyungang on April 28, 1997. It listed on the Shanghai Stock Exchange on October 18, 2000, and added an H-share listing in Hong Kong on May 23, 2025. The continuity matters. Hengrui did not emerge from venture capital, a university spinout, or a biotech shell. It came out of a traditional Chinese pharmaceutical manufacturing base and then spent decades climbing the value chain.

That origin explains why Hengrui’s culture looks different from many newer Chinese biotech names. Founder-chairman Sun Piaoyang, who took charge of the predecessor state-led company in 1990 according to public profiles and remains chairman in the 2025 annual report, built the business with manufacturing discipline first and innovation ambition second. This order of operations mattered. Hengrui learned how to make money before it learned how to sell innovation to global pharma. That gave it time, cash, and patience that many later entrants never had. It also left a legacy field-sales model that later became vulnerable when Beijing tightened procurement and anti-corruption enforcement.

The first stage of Hengrui’s listed life was scale-building. The company expanded through the familiar Chinese pharma playbook of the period: move from factory production into branded hospital products with defensible niches, build distribution depth, and push steadily into higher-value therapeutic areas. The lasting result went beyond revenue growth. The company built a nationwide commercial infrastructure that later became the launchpad for innovative drugs. The 2025 annual report still describes a large internal operating system spanning commercial excellence, marketing, medical affairs, central and provincial sales management, and market-access functions. That platform is expensive, but it is one reason Hengrui can commercialize at home more effectively than many research-focused peers.

The second stage was the innovation turn, roughly the mid-2010s through 2020. This was the period when Hengrui stopped being valued mainly as a high-quality domestic pharma company and started being valued as China’s most credible large-cap innovative-drug champion. The company pushed R&D harder, broadened therapeutic focus, and built what the 2025 annual report now describes as industry-leading, fully integrated pharmaceutical platforms across oncology, metabolic and cardiovascular disease, immunology, respiratory disease, and neuroscience. Investors rewarded that move because the Chinese market had very few established, profitable drugmakers willing to spend on innovation at Hengrui’s scale.

The third stage was the reset. That reset had several triggers, and none were cosmetic. Volume-based procurement normalized price pressure on mature products. Reimbursement access for innovative drugs increasingly came with steep concessions, even as the policy framework became more innovation-friendly at the strategic level. The medical anti-corruption campaign created fresh anxiety around the selling model of Chinese drug companies. Boardroom symbolism did not help sentiment either: Sun Piaoyang’s 2020 step-down from the chairmanship was widely noticed even though he remained deeply tied to Hengrui. The market stopped paying an open-ended multiple for “China innovation ambition” and began demanding proof of monetization.

The numbers capture that reset better than any slogan. Revenue fell from RMB 25.91 billion in 2021 to RMB 21.28 billion in 2022, while attributable net profit dropped from RMB 4.53 billion to RMB 3.91 billion. Operating cash flow collapsed to RMB 1.27 billion in 2022 from RMB 4.22 billion in 2021. The business did not break. It absorbed a policy-and-mix shock. But it did lose the aura of immunity that the market had previously granted it.

The fourth stage began in 2023 and accelerated through 2025: monetization and globalization. Revenue recovered to RMB 22.82 billion in 2023, then to RMB 27.98 billion in 2024 and RMB 31.63 billion in 2025. Net profit recovered faster, reaching RMB 7.71 billion in 2025, while operating cash flow jumped to RMB 11.24 billion. The annual report makes clear what changed. Innovative-drug sales grew, licensing revenue increased, the company’s approved innovative-drug count continued to rise, and Hengrui began converting its pipeline into cross-border deals rather than only domestic launches. That is the stage the market is trading now.

The Hong Kong listing in May 2025 was more than a financing event. Hengrui sold 224.52 million H shares at HK$44.05 per share, began trading on May 23, 2025, and recorded RMB 10.35 billion of proceeds from the H-share issuance in the 2025 cash-flow statement. Reuters reported gross proceeds of about $1.27 billion, making it one of Hong Kong’s biggest equity offerings of 2025. The listing tightened the link between Hengrui’s scientific story and international capital markets. It also created a visible A/H equity arbitrage. On 2026-06-26, the H share closed at HK$54.75; using the CFETS central parity of HKD/CNY 0.86953 that day, the H share was worth about RMB 47.6, a modest discount to the A-share close of RMB 50.04.

The decisive key nodes since then have all pointed in the same direction. In March 2025, Merck agreed to pay Hengrui $200 million upfront for global rights to HRS-5346 outside Greater China, with up to $1.77 billion in potential milestones. In July 2025, GSK struck a collaboration worth $500 million upfront and up to $12 billion in milestones across HRS-9821 and eleven other programs. In May 2026, Bristol Myers Squibb and Hengrui announced cross-licensing and collaboration agreements potentially worth up to $15.2 billion in milestones. Each transaction was structured differently, and all the milestone numbers are contingent rather than bankable. But together they rewrote the market’s assessment of Hengrui’s external relevance. This was no longer only a China launch story. It was a China-origin asset exporter.

The obesity franchise shows both the upside and the caution. Kailera’s SEC prospectus says the company entered a Hengrui license and collaboration agreement in May 2024 for ribupatide, KAI-7535, KAI-4729, and related derivatives outside Greater China, with Hengrui retaining Greater China rights. Kailera paid $100 million upfront, a $10 million technology-transfer fee, and issued Series A-2 preferred shares to Hengrui. Kailera later priced its IPO at $16 a share and began trading on Nasdaq under KLRA on April 17, 2026. This is exactly the kind of transaction Hengrui bulls want to see: a domestic discovery program turned into offshore capital formation. It is also exactly the kind of story that can be overcapitalized if investors start counting preclinical milestones and public-market enthusiasm as cash already earned.

The present stage is therefore not simple maturity. It is harvest with reinvestment. Hengrui now has enough depth to launch more innovative products domestically, enough cash to fund its own science, enough credibility to deal with global pharma, and enough scale that execution mistakes show up quickly in the numbers. That combination is why the company commands a premium. It is also why the stock is less forgiving than a pure turnaround or a low-expectation incumbent.

Financial vertical review

The broad financial arc over the last five years is not a smooth compounding line. It is a dip-and-recovery pattern that tells the story of a business model under transition stress and then under monetization repair. Revenue moved from RMB 25.91 billion in 2021 to RMB 21.28 billion in 2022, then recovered to RMB 22.82 billion in 2023, RMB 27.98 billion in 2024, and RMB 31.63 billion in 2025. Attributable net profit followed a similar path: RMB 4.53 billion in 2021, RMB 3.91 billion in 2022, RMB 4.30 billion in 2023, RMB 6.34 billion in 2024, and RMB 7.71 billion in 2025. The recovery has been real, but it was earned through mix change, not through a return to the old China selling environment.

What improved first was earnings leverage. Gross profit rose from RMB 17.79 billion in 2022 to RMB 19.29 billion in 2023, RMB 24.14 billion in 2024, and RMB 27.27 billion in 2025, while gross margin remained extremely high because Hengrui’s revenue mix increasingly reflects high-margin branded and innovative products plus licensing rather than low-margin bulk manufacturing. Even after a large R&D bill, profit before tax rose from RMB 3.97 billion in 2022 to RMB 8.71 billion in 2025. This is a good sign, but not a trivial one. In Chinese pharma, high gross margin alone proves little; Hengrui’s distinction is that it has preserved gross margin while rebuilding profit growth rather than rescuing earnings through R&D cuts.

The R&D bill is the economic key. The company reported R&D expenditure of RMB 6.35 billion in 2022, RMB 6.15 billion in 2023, RMB 8.23 billion in 2024, and RMB 8.72 billion in 2025. The company’s English overview also says R&D spending has stayed above 25% of revenue for several consecutive years, and 2025’s disclosed R&D expenditure implies roughly 27.6% of revenue. This is why Hengrui deserves to be analyzed as an innovative drug platform rather than a late-cycle branded-generic compounder. It is spending at a level that can sustain pipeline renewal, and it is doing so while remaining profitable.

Cash conversion, once an area of real concern, has improved sharply. Operating cash flow was RMB 4.22 billion in 2021, then dropped to RMB 1.27 billion in 2022 before rebounding to RMB 7.64 billion in 2023, RMB 7.42 billion in 2024, and RMB 11.24 billion in 2025. Over 2021-2025, cumulative operating cash flow was about RMB 31.8 billion against cumulative net income of about RMB 26.8 billion, an aggregate OCF/net income ratio of roughly 1.19x. That is healthy for a company of this type. The weak 2022 conversion should be read as the stress year; the last three years suggest the company can turn accounting profit into cash even while carrying a large innovation budget.

The balance sheet is one of Hengrui’s strongest strategic assets. At year-end 2025, the company had total assets of RMB 69.87 billion, total liabilities of RMB 8.07 billion, total equity of RMB 61.80 billion, and cash and cash equivalents of RMB 40.16 billion. Financing cash flow in 2025 was dominated by the H-share issuance, but even stripping that out, the underlying leverage profile stayed conservative. This matters because most Chinese biopharma stories are capital-markets stories first and operating stories second. Hengrui is the reverse. It can fund its pipeline internally and still return cash to shareholders.

There are, however, two balance-sheet items that deserve attention. First, trade and bill receivables increased by RMB 1.06 billion in 2025. That is manageable, but investors should watch it because distribution-heavy Chinese pharma businesses can hide channel stress in receivables. Second, capitalized development costs not yet available for use rose to RMB 4.88 billion at December 31, 2025, from RMB 3.84 billion a year earlier. This is not automatically a red flag. It reflects advancing programs. But it also means more of the future return on R&D is sitting on the balance sheet waiting to be proven in the clinic and the market.

Returns on capital have also recovered but not in a straight line. The company’s weighted average ROE was 13.96% in 2021, 10.89% in 2022, 10.99% in 2023, 14.73% in 2024, and 14.26% in 2025. The slight decline in 2025 from 2024 is not alarming; equity expanded sharply after the Hong Kong fundraising, and the company ended the year far better capitalized. What matters is that Hengrui’s recovery in ROE came alongside a structurally larger innovation budget. In other words, the company is not harvesting old assets at the expense of future returns. It is expanding its capital base while keeping the cash engine alive.

The most useful way to read Hengrui’s financials is this: 2022 was the year the old model was repriced; 2023 proved the company could stabilize; 2024 and 2025 showed that innovation and licensing were becoming large enough to carry the group back to growth. The question for investors now is not whether recovery happened. The question is how much of the next stage is already embedded in a 40x-plus earnings multiple.

Price and valuation history

Hengrui’s capital-market history is a story of changing labels. For years the stock was treated as China’s closest large-cap answer to a “high-quality growth pharma” franchise. Investors paid up because Hengrui combined three things rarely found together in mainland healthcare: scale, profitability, and internal R&D ambition. That premium made sense as long as revenue kept compounding and the policy environment still tolerated the economics of high-value domestic hospital products.

The rerating downward came when those assumptions stopped looking permanent. Revenue and profit fell in 2022, cash conversion weakened, and the Chinese policy environment kept reminding investors that old hospital economics could be rewritten quickly. By August 2023, Reuters reported Hengrui had lost nearly RMB 50 billion in market value in less than two weeks during the stepped-up anti-graft crackdown. That episode did not create the valuation reset by itself, but it captured the new reality: Hengrui might still be the best domestic innovative-drug platform of scale, yet it was operating in an ecosystem where policy could still hit the equity story hard and fast.

The rerating upward resumed when the market stopped looking only at China field execution and started looking at external asset monetization. The Hong Kong listing priced at the top of range in May 2025. Reuters then reported the GSK deal in July 2025, sending Shanghai shares up 6.6% and Hong Kong shares up 8.5% on the day. In May 2026, the Bristol Myers Squibb package pushed the Shanghai shares about 8% higher. Those reactions tell you what the market is paying for now. It is paying for proof that Hengrui’s science is exportable and that the company can become a repeat dealmaker without losing control of its domestic platform.

At the current A-share close of RMB 50.04, Reuters shows a prospective P/E of 47.5x and an ex-items P/E of 40.8x, while Google Finance shows a market cap for the H share of HK$357.39 billion and a P/E of 40.81x as of 2026-06-26. Those readings are not identical, but they agree on the big point: Hengrui remains a premium-rated stock. The multiple is no longer at the untouchable heights of its peak-growth mythology, yet it is still far above what the market grants to slower-growth Chinese pharma names. Current valuation is therefore neither distressed nor euphoric. It is demanding.

Business model and moat

Hengrui’s revenue machine now runs on two connected but economically different engines. The first is the domestic and regional sale of pharmaceutical products. In 2025, product sales contributed RMB 28.01 billion of revenue. The second is licensing revenue, which reached RMB 3.39 billion in 2025. The product business pays the bills, supports scale, and gives Hengrui a reason to exist independent of capital markets. The licensing business reveals how much the outside world thinks Hengrui’s science is worth. Investors have to value both, but not with the same certainty.

The product side is broad rather than concentrated. The company describes a portfolio spanning oncology, metabolic and cardiovascular disease, immunology and respiratory disease, neuroscience, anesthesia, pain management, imaging, and related areas. That breadth does real work. It lowers single-product risk, supports physician relationships across departments, and gives the company more shots on goal for reimbursement inclusion. It also explains why Hengrui’s domestic commercial platform remains heavy: the business is large enough to need national sales management, medical affairs, and provincial market access rather than a single specialty sales force.

The licensing side is more subtle. The annual report makes clear that licensing contracts may contain multiple performance obligations, including grants of IP rights, R&D services, options, milestones, and royalties. In 2025, revenue from contracts with customers included RMB 3.39 billion of licensing revenue, while remaining transaction prices allocated to unsatisfied or partially unsatisfied obligations totaled RMB 3.08 billion, of which RMB 1.16 billion is expected after one year. That tells investors three things. First, the deal pipeline is meaningful. Second, some future revenue is already visible. Third, much of the public “headline deal value” is still constrained variable consideration and should not be treated as earned.

The company’s cost structure has classic pharma characteristics. Manufacturing cost of sales is modest relative to revenue, which is why gross margins are so high. The large fixed-cost buckets are selling, distribution, administration, and R&D. In 2025 these amounted to RMB 9.11 billion, RMB 3.07 billion, and RMB 6.96 billion respectively under IFRS presentation, with total R&D expenditure beyond expensed R&D shown separately at RMB 8.72 billion. This creates operating leverage when new products scale successfully, but it also means earnings can disappoint sharply if revenue normalization occurs while the R&D base remains elevated. Hengrui’s cost structure is forgiving on the factory floor and demanding in the income statement.

The first real moat is R&D scale with commercial feedback. Hengrui’s 2025 annual report says the company had 24 Class 1 innovative drugs and five Class 2 new drugs approved for marketing in China by year-end. Its English corporate profile says Hengrui operates 15 R&D centers globally and employs more than 5,600 R&D professionals. Scale alone is not a moat; many companies waste money at scale. Hengrui’s moat lies in the loop between discovery, development, China market access, and increasingly outbound partnering. That loop is difficult to imitate because it requires both scientific depth and an existing earnings engine.

The second moat is domestic commercialization infrastructure. The annual report’s discussion of commercial excellence, medical affairs, central and provincial sales management, and market access reads like the operating manual of a very large launch platform. This is not glamorous, but it matters in China, where getting innovative products approved is only the start and real value depends on hospital listing, reimbursement, provincial execution, and physician adoption. Many biotech peers can do discovery and clinical development. Far fewer can handle national commercialization at scale.

The third moat is capital strength. Hengrui ended 2025 with more than RMB 40 billion in cash and just RMB 8.07 billion in total liabilities. That balance sheet changes strategic behavior. It lets Hengrui negotiate partnerships without funding desperation, invest through cycle troughs, repurchase A shares for employee stock ownership schemes, and absorb regulatory or clinical disappointments without threatening the franchise. In a sector where financing windows routinely define winners and losers, that is a real strategic asset.

The moat that deserves more caution is the China sales network itself. It remains powerful, but it is not a timeless fortress. Anti-corruption campaigns, procurement reform, and reimbursement bargaining have already reduced the economic value of the old field-force-heavy model. Hengrui knows this, which is one reason it is leaning harder into innovation and outbound licensing. The right conclusion is not that the old sales machine no longer matters. It is that its standalone worth is lower than the market once assumed, and its main strategic value now lies in launching innovative products rather than defending legacy hospital brands.

Governance is better than average for Chinese pharma but not immaculate. The board and senior management are experienced, founder influence remains clear, and the return of Sun Piaoyang to the chair positions strategic control in familiar hands. The company proposed a 2025 final dividend of RMB 2.0 per ten shares, in line with the prior year, and its 2025 filings show both dividends and share repurchases for employee ownership schemes. That is not aggressive shareholder return, but it suggests discipline rather than empire building. I did not find evidence in the current filings reviewed of a fresh accounting controversy or auditor instability; Ernst & Young and EY Hua Ming signed off on the 2025 statements.

Industry and cycle

China pharma is a good place to get the industry wrong if one uses a single label. Demand is defensive. Pricing is political. Innovation economics are cyclical in capital markets, even when patient demand is not. The Frost & Sullivan industry report in Hengrui’s Hong Kong listing materials estimated that China’s pharmaceutical market grew only from RMB 1.53 trillion in 2018 to RMB 1.62 trillion in 2023, a 1.1% CAGR, but forecast growth to RMB 2.34 trillion by 2028, with biologics growing much faster than chemical drugs and traditional Chinese medicine. More importantly for Hengrui, the same report estimated the China NME drug market had grown from RMB 196.7 billion in 2019 to RMB 367.5 billion in 2023 and could reach RMB 734.9 billion by 2028. The profit pool is moving toward innovative therapies even while the broader industry becomes harsher on mature products.

That is why Hengrui belongs to a policy cycle and a technology-iteration cycle more than to a normal economic cycle. Cancer incidence, aging, chronic disease prevalence, and healthcare spending do not collapse in recessions the way property or autos do. What changes instead is reimbursement policy, review timelines, physician access, and the market’s willingness to capitalize distant pipeline cash flows. Beijing’s policy stance has become more favorable to innovation in principle. The State Council guideline released at the start of 2025 called for deeply reforming drug and medical-device regulation to support high-quality development. NMPA materials later detailed a 30-day clinical-trial review pathway for eligible innovative drugs. The 2025 NRDL update added 114 new drugs, including 50 Class 1 innovative drugs, while still preserving the familiar reality that reimbursement often demands price concessions averaging above 60%. Hengrui benefits from the support side and still has to live with the pricing side.

The industry is also changing because global pharma has started shopping more aggressively in China. Reuters reported that analysts expect China biotech licensing to hit another record in 2026 as Western incumbents search for pipeline replenishment ahead of major patent cliffs. Hengrui is unusually well positioned for that phase because it does not need a licensing deal just to stay alive. It can choose, sequence, and structure deals from a position of balance-sheet strength. That does not eliminate execution risk, but it does improve bargaining power.

Geopolitics is a secondary but real factor. Hengrui is not an export-controls story in the way advanced semiconductors are, but cross-border clinical development, overseas manufacturing, global partnering, and foreign investor appetite can all be reshaped by U.S.-China tension. Reuters has reported broader disruption to China pharma R&D planning from Sino-U.S. tensions, including project redesign and local supply-chain adjustments by sector participants. For Hengrui, the more relevant issue is not a single sanction risk. It is whether Chinese-origin science remains institutionally investable and licensable to Western multinationals at today’s pace. So far the evidence says yes. That is a positive, but it is not irreversible.

Horizontal competitor analysis

The right peer set is not a handful of generic Chinese drugmakers and not a basket of pre-profit biotech names. Hengrui’s real comparison group is mixed: Hansoh as the closest domestic profitable innovator, Innovent as a China innovation pure-play that has now crossed into profitability, CSPC as a large commercial group pushing harder into innovation and BD, and BeOne as the best proof that China-developed oncology assets can scale globally. This is a case for Scenario C: there are several meaningful peers, but none matches Hengrui perfectly.

Hansoh is the closest domestic mirror, though smaller. Official 2025 annual materials show Hansoh generated about RMB 15.03 billion of revenue and RMB 5.56 billion of profit in 2025. Innovative and collaborative products have become a very large share of its revenue. The stock traded at HK$28.76 on 2026-06-26. Hansoh today looks like a cleaner, narrower version of what Hengrui wants to be: a profitable Chinese innovator with increasing BD relevance. Hengrui’s advantage is broader modality exposure, bigger cash resources, and a deeper commercial footprint. Hansoh’s advantage is that the market pays a lower valuation for a business whose innovation pivot is already clear but less heavily capitalized.

Innovent is a different comparison. Official 2025 annual results show revenue of RMB 13.04 billion, gross margin of 87.2%, and approximately RMB 2.0 billion of profit, its first full year of profitability. That is a major milestone. Innovent is more biologics-heavy, more concentrated in a narrower set of therapeutic franchises, and more directly associated with the Chinese biotech wave. Hengrui is broader, more cash-generative, and less dependent on a few hero assets. Innovent’s strength is sharper innovation identity. Hengrui’s strength is resilience. Customers and investors buy those things for different reasons. Physicians buy Innovent for specific molecules. Investors buy Hengrui because there are more ways for the franchise to keep winning.

CSPC is the useful cautionary peer. Official investor-relations materials show first-quarter 2026 revenue of RMB 6.47 billion, down 7.8%, and attributable profit of RMB 860 million, down 41.8%. Its 2025 annual results showed attributable profit of RMB 3.88 billion, below 2024. CSPC is trying to do more of what Hengrui is already further along in doing: move the valuation center from legacy commercial franchises toward innovation and outbound licensing. Reuters separately reported CSPC’s large 2025-26 AstraZeneca deals, confirming the market will reward Chinese companies that externalize discovery value. The difference is that Hengrui’s domestic innovative portfolio is already more mature and its financial buffer is much stronger. CSPC shows what Hengrui would look like if the innovation pivot were still not dominant enough to offset legacy drag.

BeOne sits above the domestic peer set because it proves the far end of the path. Official 2025 financial results showed total revenue of $5.3 billion, up 40%, and GAAP net income of about $286.9 million, driven by BRUKINSA’s global success. Reuters reflects the same company under its new identity as BeOne Medicines AG. Hengrui is not there. It does not yet have a truly global commercial oncology franchise of that scale. But BeOne matters because it anchors the upper bound of what investors are willing to believe about China-origin innovation. Hengrui’s premium rests partly on the idea that it can export more of its pipeline and, over time, globalize more than the old A-share market once imagined.

What each company became matters more than a raw multiples table. Hansoh became a focused, profitable Chinese innovator whose outside-option value to multinationals is rising. Innovent became the flagship of the biologics generation and then graduated into profitability. CSPC became the example that BD can reframe a legacy mixed portfolio, but only up to a point. BeOne became the global benchmark for China-developed oncology commercialization. Hengrui became the only large Chinese listed drugmaker that can plausibly combine domestic commercialization breadth, self-funded innovation, and repeat outbound partnering at scale. That is its real niche.

From a valuation perspective, Hengrui is not obviously cheap against this group. Hansoh’s market cap around HK$177 billion and Hengrui’s H-share market cap around HK$357 billion imply the market is paying roughly double for a business with roughly double the sales but a significantly larger pipeline franchise. Innovent’s ~HK$132 billion market cap against RMB 13.04 billion of 2025 revenue says the market still pays heavily for high-growth innovation even after profitability. CSPC’s ~HK$76 billion market cap reflects slower growth and legacy drag. BeOne’s much larger global revenue base and roughly RMB 198 billion Shanghai market cap show what happens when innovation becomes globally monetized rather than domestically anticipated. Hengrui’s premium is justified by quality and breadth. The open question is whether the premium should be this high before obesity, radiopharma, and more overseas partnerships are de-risked.

Ecologically, Hengrui is the leader in China’s domestic innovative-pharma middle ground. It is not the lowest-risk cash cow in the industry, because it still spends too much and tries too much for that label. It is not the best global pure-play innovator either, because too much of its economics still run through China. Its niche is more useful than either label suggests: it stands where China reimbursement, China commercialization, and global licensing are now intersecting. If the industry goes through another price war in legacy products, Hengrui’s position should strengthen relative to more mixed peers. If the industry goes through a sharp innovation de-rating, Hengrui will weaken less than biotech-style peers but more than plain vanilla defensive pharma.

Current fundamentals and bull bear divergence

The latest quarter was good, though not clean enough to end the debate. In the first quarter of 2026, Hengrui reported revenue of RMB 8.141 billion, up 12.98% year on year, attributable net profit of RMB 2.282 billion, up 21.78%, and deducted net profit of RMB 2.172 billion, up 16.59%. Total R&D investment was RMB 2.224 billion, of which RMB 1.651 billion was expensed. Innovative-drug sales were RMB 4.526 billion, up 25.75%, accounting for 61.69% of drug sales revenue. Those are the figures of a business whose innovation mix is still climbing and whose earnings are not being bought by cutting science.

What the market is really trading now is the combination of three things. The first is a credible shift in revenue mix toward innovative products. The second is the idea that outbound licensing can become a durable second leg of monetization. The third is a policy backdrop in China that, while still price-conscious, has become more openly supportive of innovative drugs from a regulatory and reimbursement-system design perspective. That is a stronger setup than Hengrui had in 2021 or 2022. It still does not remove the fundamental lumpiness of business-development revenue.

The market narrative may also be getting ahead of what filings strictly confirm. The annual report clearly shows licensing revenue of RMB 3.39 billion in 2025, up from RMB 2.70 billion in 2024. The first-quarter 2026 company disclosure visible in the quarterly report screenshot does not break out licensing revenue separately, though the math implies roughly RMB 0.80 billion of non-drug revenue in the quarter. That is consistent with the widely cited “about RMB 787 million” number, but I cannot verify that exact figure from the extracted quarterly filing lines reviewed here. Where the market gets sloppy is in treating every headline milestone number announced with Western partners as if it has similar probability and timing. The filings themselves warn against that interpretation through their revenue-recognition policy.

The bull case rests on evidence, not mood. First, Hengrui’s commercial business is now strong enough to support very high R&D intensity without leverage stress. Second, the innovative-drug sales mix is no longer aspirational; it is visibly dominant within drug sales. Third, Western counterparties keep validating the pipeline. Merck, GSK, Bristol Myers Squibb, and Kailera are not paying for sentiment. They are paying for access. Fourth, the company now has a dual-listed capital structure and a cash balance large enough to fund both the base business and major clinical programs. If those facts persist, the market can justify keeping Hengrui on a persistent premium multiple.

The bear case also rests on evidence. First, the stock is already priced like a company whose next stage is largely pre-validated, even though much of the overseas deal value is contingent. Second, reimbursement and procurement remain structural pressures on the legacy base that still funds the innovation engine. Third, some current enthusiasm is concentrated in obesity and cross-border licensing, two areas where valuation can move faster than actual cash realization. Fourth, anti-corruption and compliance pressure in China has not vanished; it can still interrupt execution and compress sentiment quickly. Fifth, the current quarter’s mix strength is impressive, but full validation requires several more quarters of consistent innovative-drug growth without being masked by licensing volatility.

The clearest way to frame the divergence is this: bulls think Hengrui is crossing the threshold from “China innovation promise” to “China innovation monetization.” Bears think the market is paying a global-innovation multiple for a business whose domestic base is still subject to Chinese policy friction and whose offshore monetization remains episodic. That is not a trivial disagreement. It is the whole stock.

Valuation analysis

Historically, Hengrui’s valuation has moved with which part of the business investors believed was dominant. When the market believed the company was a near-perfect domestic innovation steward, the multiple expanded sharply. When it looked like policy could damage the legacy base faster than innovation could replace it, the multiple compressed. Today’s roughly 41x trailing earnings and high-single-digit sales multiple place the stock well above ordinary mature-pharma territory but below the most momentum-driven periods associated with China biotech exuberance. This is still a premium valuation centered on confidence rather than fear.

Against peers, Hengrui deserves some premium. Hansoh is profitable but smaller and more narrowly scoped. Innovent is growing fast and has reached profitability, yet it does not have Hengrui’s balance-sheet strength or diversified domestic commercial base. CSPC is cheaper for good reason. BeOne is proof that true global oncology scale earns a different valuation altogether. The problem is not that Hengrui is expensive relative to all peers. The problem is that, at the current price, the premium already assumes more of the good future than the conservative investor should comfortably pre-pay.

Cash-flow passthrough first. Over 2021-2025, cumulative operating cash flow was about RMB 31.8 billion against cumulative attributable net income of about RMB 26.8 billion, so the five-year OCF/net-income ratio was roughly 1.19x. That means reported profits have converted into cash reasonably well over the cycle even though single-year volatility has been large. On maintenance versus growth capex, the 2025 cash-flow statement shows RMB 1.03 billion of property, plant and equipment purchases, RMB 93.5 million of land-use-right purchases, and RMB 1.84 billion of intangible additions. Depreciation, amortization, and right-of-use depreciation together were about RMB 942 million. I therefore treat roughly RMB 0.9–1.0 billion as maintenance capital intensity and most spending above that as growth capex, especially capitalized development work. On that basis, owner earnings remain close to reported earnings rather than materially below them. The gap between headline P/E and owner-earnings P/E is not large enough to force a different valuation basis.

For an absolute valuation, a simple one-year P/E is too crude because the business mix now blends commercial pharma and pipeline monetization. A pure DCF would overstate precision. The most sensible approach is to value normalized owner earnings under three scenarios, with explicit caution on contingent milestones. My base case assumes continued innovative-drug growth, modest ongoing licensing revenue, and no heroic capitalization of milestone headlines. My conservative case assumes slower innovation growth, flatter licensing, and a lower multiple as the market re-rates Hengrui back toward a high-quality domestic innovator rather than a quasi-global growth stock. My optimistic case assumes repeat outbound deals, successful mix upgrade, and stronger obesity/pipeline optionality support. This is valuation-scenario analysis within a research framework, not investment advice.

The business reason behind these numbers is simple. Hengrui no longer needs a distressed multiple because the financial base is too strong. But it also does not deserve a “pay anything” multiple because too much of the external-deal narrative depends on clinical progress and milestone realization that are not yet contractual cash. The conservative case is not a disaster case. It is what Hengrui looks like if it remains very good without becoming dramatically better. The base case says the current price is close to fair if one grants that the transition is working. The optimistic case requires more than one more deal headline. It requires repeatability.

Expectation-gap analysis points to one central issue: the market is already assuming innovation and BD quality are durable. That means the next big gaps will not come from yet another licensing press release alone. They will come from the composition of revenue, the quality of operating cash flow, and the extent to which innovative-drug growth can remain strong even when licensing normalizes. At the next major result, investors should care most about innovative-drug sales growth, ex-licensing revenue growth, operating-cash-flow conversion, and any clearer breakout of licensing recognition versus milestone potential. Those are the variables most likely to change the bull or bear view.

The margin-of-safety recheck is not flattering. At RMB 50.04, the stock trades above the value implied by my conservative scenario. That means the margin of safety is zero on a conservative basis. The most fragile assumption in the base case is not commercial breadth. It is the persistence of premium valuation while the market waits for externally validated pipeline progress. If I cut the base-case earnings/quality assumption to 70% on the valuation bridge, the base-case fair value falls into the high-30s to low-40s. If earnings were merely flat for three years and the multiple drifted down modestly, the annualized return from today’s price would likely trail China’s 10-year government-bond yield. This is a classic good-company-bad-price risk, or at least good-company-full-price. Margin-of-safety sufficiency verdict: none.

Risk analysis

The first major risk is domestic pricing pressure on the legacy and maturing portfolio. Probability is medium; impact is high. The observable indicators are deeper-than-expected NRDL concessions, inclusion of more Hengrui products in volume-based procurement, or a rise in innovative-drug volume without sufficient value retention. The transmission path is direct. Lower realized prices hurt product gross profit, which limits the cash available to support the R&D engine and, if persistent, narrows the valuation premium investors are willing to pay for Hengrui’s platform. The strategic point is that Hengrui can withstand pricing pressure better than most peers, but it cannot ignore it.

The second risk is business-development quality illusion. Probability is medium; impact is high. The company really is winning large licensing deals, but milestone-heavy structures can make the franchise look more predictable than it is. The indicators are the ratio of recognized licensing revenue to announced headline deal values, changes in remaining performance obligations, and whether new deals increasingly contain non-cash consideration or early-stage options rather than plain-cash economics. If the market begins to suspect that Hengrui’s licensing franchise is episodic rather than repeatable, the multiple can compress even if the underlying product business remains healthy. This is precisely the danger of valuing Hengrui more like a platform biotech while it is still fundamentally a commercial pharma company.

The third risk is obesity and next-wave pipeline disappointment. Probability is medium; impact is high. Kailera’s public-market success and investor enthusiasm around obesity have increased the reputational value of Hengrui’s GLP-1/GIP assets, but that also raises the bar. Delayed readouts, weaker-than-hoped differentiation, or a more crowded global obesity market would not only reduce the value of that program. They would undermine the narrative that Hengrui sits at the center of the most valuable therapeutic category in global biotech. The transmission path runs first through sentiment, then through licensing optionality, and eventually through the multiple.

The fourth risk is compliance disruption in China. Probability is medium; impact is medium to high. The 2023 anti-graft crackdown showed how fast healthcare shares can derate when investors worry that the commercial model is under scrutiny. Hengrui says it operates with a compliance-oriented model and the broader regulatory trend may favor companies that can operate more cleanly. But the sales base is still large, and even temporary disruption can produce stock-price pain long before it produces permanent business damage. The indicator is not just enforcement headlines. It is also sales-expense efficiency, receivables quality, and evidence that product growth is being carried by real clinical adoption rather than distribution push.

The fifth risk is pure valuation compression. Probability is high; impact is medium to high. A 40x-plus earnings multiple leaves little buffer if interest rates stay higher than the market expects, global investors rotate away from Chinese healthcare, or earnings growth normalizes after a run of deal-related optimism. The indicator is simple: if Hengrui keeps posting good but not spectacular quarters and the stock no longer re-rates on deal headlines, the market may gradually move the acceptable multiple from “globalizing innovation leader” toward “premium domestic pharma.” The business could keep improving while the share price stalls or falls. That is permanent capital risk only if the investor overpays and then refuses to reassess.

Catalysts and tracking indicators

Positive catalysts are not hard to imagine. Another year in which innovative-drug sales keep rising as a share of total drug sales would strengthen the quality of revenue. A cleaner disclosure split between recurring product revenue and licensing revenue would improve investor confidence in earnings quality. Additional cross-border deals with meaningful upfront cash would validate the exportability of the pipeline without requiring the market to price only distant milestones. Faster NMPA review under the newer innovation-supportive pathways would help, especially for large commercial opportunities. And if Hengrui can show obesity and radiopharma progress without allowing those themes to dominate investor imagination, the company can gradually earn a more durable premium.

Negative catalysts are just as concrete. A quarter in which innovative-drug growth slows materially, licensing revenue falls away, and cash conversion softens would prompt the market to ask whether 2025-26 was a peak narrative period. A large NRDL price cut on a key innovative product would reopen concerns about the monetization ceiling of domestic innovation. A setback in obesity or a cooling-off in global China-asset licensing would hit the multiple harder than it would hit near-term earnings. And any renewed compliance-driven sector selloff in China healthcare would likely punish Hengrui disproportionately because it is liquid, large, and widely owned.

These indicators matter because they separate the real business from the story told around it. Innovative-drug mix tells you whether the strategic transition is still advancing. Ex-licensing revenue growth shows whether the domestic commercial engine is strong on its own. OCF/net income and receivables tell you whether accounting profit is turning into cash. R&D intensity tells you whether Hengrui is still funding its future rather than milking its past. Gross margin and net cash show how much operating room management still has. Remaining licensing obligations reveal whether the deal machine has backlog or only headlines. The multiple tells you whether the market is asking the company to be merely good or almost flawless.

Cross synthesis summary

Vertically, Hengrui has proven one capability above all others: it can reinvent the source of its profits without losing the basic ability to generate them. That sounds simple. It is not. Plenty of Chinese pharmaceutical companies built commercial scale in the old domestic system. Far fewer survived the shift toward centralized procurement, innovation-heavy capital allocation, and stricter compliance expectations while preserving both profitability and scientific ambition. Hengrui did. That is the deepest fact in the whole report. The company came out of a manufacturing lineage, moved into branded scale, took the pain of policy and mix transition, and re-emerged as a profitable innovation platform with genuine outbound relevance.

Its past success was not luck, but it was never solely genius either. Era tailwinds clearly helped. China’s healthcare spending rose, the old hospital channel was economically attractive for years, and capital markets once rewarded any credible innovation narrative generously. Yet those tailwinds alone do not explain why Hengrui still stands where many others faded. Management made choices that turned transient advantages into durable capabilities: reinvest heavily in R&D, keep the balance sheet conservative, build internal commercialization rather than outsource the franchise, and keep enough breadth that no single policy change could break the company. Those choices are still visible in 2025-26. The current cash balance, the size of the R&D bill, and the broad therapeutic footprint are their financial residue.

Horizontally, Hengrui’s real edge versus competitors is breadth with discipline. Hansoh is elegant but smaller. Innovent is sharper but narrower. CSPC is commercially large but more mixed. BeOne is more global but substantially different in business emphasis. Hengrui sits in the middle with the most optionality: domestic product cash, one of the biggest self-funded pipelines, enough balance-sheet strength to negotiate rather than plead, and an increasingly credible record of converting science into external validation. Its weakness is not scientific poverty or financial fragility. Its weakness is that a broad platform invites investors to overcapitalize optionality and underprice the cost of being broad. A company trying to do many valuable things at once can still be a poor stock if investors insist on paying upfront for all of them.

That, in turn, is the central valuation problem. The current price is rewarding real progress, but it is also pre-spending future progress. The market is not misjudging whether Hengrui is a serious company. It is misjudging the timing and certainty of the next layer of monetization. Licensing headlines are valuable evidence of platform quality, yet they do not deserve to be capitalized like annuities until a pattern is visible across several years, several counterparties, and several realized milestone paths. Obesity optionality is valuable, yet it does not deserve to dominate the investment case before the relevant programs are much further de-risked. China policy is more supportive of innovation, yet the same system still demands price concessions and still can disrupt commercial execution abruptly. The stock is therefore easiest to like as a company and hardest to like as a fresh buy.

For the next year, the critical variable is quality of growth rather than absolute growth. Investors should watch whether innovative-drug sales continue taking share, whether ex-licensing revenue stays healthy, whether operating cash flow keeps tracking or exceeding net income, and whether management gives a cleaner map of what portion of licensing economics is recurring versus event-driven. For the next three years, what matters is whether Hengrui can institutionalize outbound licensing without turning into a headline-dependent stock. For the next five years, the deepest question is whether the company can produce at least one or two franchises that carry more of their economic value globally rather than mainly through the China system.

Hengrui becomes a better investment under one of two conditions. Either the business keeps improving and the stock stops asking for perfection, or the price falls enough that investors can buy the proven cash engine and get the platform option free or close to free. The current setup offers neither. It offers a premium company at a roughly fair-to-full price. I would overturn that judgment if the company sustained another year of strong innovative-drug growth while operating cash flow remained robust and the market multiple drifted down into the low-30s on earnings. I would also revisit if Hengrui began disclosing licensing economics with enough granularity to prove that a meaningful portion of what now looks lumpy is becoming durable. Conversely, I would become materially more cautious if innovative-drug mix stalled, if receivables and working capital weakened meaningfully, or if a major obesity or high-profile partnered asset failed and the market still tried to defend the same premium multiple.

Bull and bear reasons

Bull reasons

• Hengrui remains one of the few Chinese pharma companies combining very high R&D intensity with solid profitability and strong cash conversion, as shown by RMB 8.72 billion of 2025 R&D expenditure, RMB 7.71 billion of net profit, and RMB 11.24 billion of operating cash flow.
• The strategic mix shift is visible in the latest quarter: innovative-drug sales reached RMB 4.526 billion in Q1 2026 and accounted for 61.69% of drug sales revenue.
• Global counterparties keep validating the pipeline through real transactions, including Merck, GSK, Bristol Myers Squibb, and the Kailera obesity platform arrangement.
• The balance sheet is unusually strong for the sector, with RMB 40.16 billion of cash and cash equivalents and only RMB 8.07 billion of total liabilities at end-2025.
• China’s policy framework is becoming more supportive of innovative-drug development and access even while pricing remains disciplined.

Bear reasons

• The current share price already sits above my conservative valuation and leaves no margin of safety if licensing momentum or the premium multiple softens.
• Licensing economics are meaningful but inherently lumpy, and headline milestone values should not be capitalized as if they were recurring cash earnings.
• China’s reimbursement and procurement system still compresses pricing power even for innovative drugs, with 2025 NRDL negotiations again involving average price cuts above 60%.
• The commercial model remains exposed to policy and compliance shocks, as the 2023 anti-graft episode showed.
• Investor enthusiasm around obesity and cross-border BD can outrun the pace of actual data maturity and cash realization.

Pre mortem

One plausible 50% drawdown script runs through the obesity narrative. In 2027, follow-on global obesity data from Hengrui-origin assets disappoint on efficacy or tolerability versus the best competing GLP-1/GIP programs. Kailera sentiment cools, Hengrui’s obesity option value is marked down, and investors stop paying a premium for “hidden global obesity upside.” At the same time, innovative-drug growth in China slows from the mid-20s to high single digits because reimbursement gains come with heavier pricing pressure. If the market then compresses the stock from roughly 40x earnings toward 22x-25x, a halving is fully possible even without a balance-sheet problem.

A second script runs through quality-of-earnings disappointment. Imagine that through 2027 Hengrui still reports respectable revenue growth, but licensing revenue swings lower, ex-licensing product growth slows, receivables rise faster than sales, and operating cash flow slips below net income for several periods. The market then decides it paid a global-platform multiple for what is still mainly a China product company with event-driven BD income. If the multiple resets sharply while earnings estimates are cut only modestly, the stock could lose half its value without any one catastrophic clinical failure.

Final research conclusion

Hengrui is a serious company. It has already done the hard part that many Chinese healthcare stories never get through: build a cash engine, absorb a policy shock, preserve scientific ambition, and come out the other side with both profitability and strategic relevance intact. The proof is in the numbers. Revenue recovered strongly after the 2022 trough. Net profit and operating cash flow are now materially above pre-reset levels. The balance sheet is exceptionally strong. The pipeline has attracted repeated overseas partners. This is not promotional quality; it is operating quality.

The problem is price, not franchise. At RMB 50.04, the stock looks roughly fair if one believes the current transition keeps working, but it does not offer enough protection if licensing outcomes stay uneven, obesity enthusiasm cools, or China policy again reminds investors that value capture in pharmaceuticals is never purely scientific. What worries me most is not the company’s ability to innovate. It is the market’s willingness to pay today for a future that is improving but not yet fully earned. What would change my mind is either a cheaper entry point or another year in which mix quality, cash conversion, and cross-border monetization all keep strengthening while the multiple stays disciplined.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: A rare high-quality China pharma platform, but today’s price already discounts much of the innovation-monetization upgrade.
• Three price signals
  • 【Ideal Buy Price】34–36 RMB Basis: roughly a 20% discount to my conservative fair-value band of RMB 41–43 per share.
  • Acceptable hold price: 45–55 RMB
  • Clearly overvalued price: 64–68 RMB
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A buy becomes attractive below RMB 36, or at a somewhat higher price only if the company delivers another year of strong ex-licensing growth, healthy cash conversion, and repeatable BD monetization. The opportunity cost of waiting is that Hengrui could continue compounding operationally while the stock merely moves sideways rather than falling.
• Target holding horizon: 3–5 years
• Expected annualized return
  • Conservative: about -5% to -3%
  • Base: about 0% to 3%
  • Optimistic: about 6% to 9%
• Max-loss risk: roughly 45%–55% in a combined scenario of obesity/pipeline disappointment, softer licensing realization, and multiple compression toward the low-20s.
• Reassessment-trigger signals
  • If innovative-drug sales share of drug sales falls below 58% for two consecutive quarters.
  • If operating cash flow trails net income for a full year and receivables keep outgrowing revenue.
  • If a major outbound deal pipeline fails to convert into recognized revenue backlog or meaningful milestones.
  • If gross margin falls below 83% for two consecutive quarters.
  • If policy changes force materially deeper-than-expected NRDL or VBP price cuts on key innovative products.

【Valuation Range】

• current: 50.04 (close as of 2026-06-26)
• bear (conservative · ideal buy zone): [34, 36]
• base (fair · acceptable hold zone): [45, 55]
• bull (optimistic · above the clearly-overvalued line): [64, 68]

Key data tables

† RMB bn except ROE. ‡ 2024 R&D expenditure comes from the 2025 annual-report summary under IFRS.

The numbers show why the stock is difficult. The company’s recovery since 2022 is genuine and broad-based. Yet that same recovery has already repaired sentiment and lifted valuation back into premium territory. The better the financial table looks, the less forgiving the entry price becomes.

† RMB bn except mix percentage.

This quarter matters because it confirms that the mix shift is not theoretical. It also shows why investors need to read company wording carefully: the more-than-60% figure refers to drug-sales mix, not necessarily total revenue mix.

† “Current market reference” uses the latest web-captured market quote available around 2026-06-26. ‡ BeOne reports in U.S. dollars; others shown in reported currency.

The peer picture explains Hengrui’s premium. It is larger and more diversified than the domestic innovation cohort, but it has not yet achieved the globally scaled commercialization that justifies the kind of valuation investors give the best international oncology winners.

Research uncertainties

• I could verify from primary filings that Hengrui had 24 Class 1 innovative drugs and five Class 2 new drugs approved in China by end-2025, but I could not directly confirm from the reviewed filing excerpts the exact “90+ clinical molecules” and “8 self-developed radiopharmaceuticals” counts often cited in secondary materials. I therefore avoid treating those exact counts as confirmed facts here.
• The widely cited Q1 2026 licensing-revenue figure of about RMB 787 million appears directionally consistent with the quarterly revenue bridge, but the extracted quarterly disclosure I reviewed did not separately show that line item. I treat it as plausible but not fully verified.
• I did not verify the original 2000 A-share IPO price from a primary accessible filing in the materials reviewed, although the listing date and the fact that 40 million A shares were initially issued are confirmed.
• Because part of Hengrui’s value now sits in contingent licensing milestones and option-style economics, any point estimate of intrinsic value is less stable than for a plain commercial pharma company. The scenario analysis is therefore more reliable than any single target price.

Sources

Primary materials were the 2025 annual report and annual-results announcement, the 2026 first-quarter report, the 2025 Hong Kong listing prospectus and allotment results, the company’s official site and investor materials, the Bank of China and CFETS exchange-rate references, and official Chinese policy publications from the State Council and NMPA. These were supplemented by Reuters for deal announcements, share-price reaction, and sector context, plus Kailera’s SEC prospectus and Nasdaq listing materials for the obesity NewCo path.

Other tickers mentioned

• 03692.HK: Hansoh, the closest domestic profitable innovative-pharma peer
• 01801.HK: Innovent, a high-growth China innovator that recently reached full-year profitability
• 01093.HK: CSPC, a large mixed portfolio peer also using outbound licensing to reshape its valuation
• 688235.SHG: BeOne Medicines, the globalizing oncology benchmark for China-origin innovation
• BMY.US: Bristol Myers Squibb, Hengrui’s May 2026 cross-licensing and collaboration counterparty
• MRK.US: Merck, Hengrui’s March 2025 cardiovascular licensing counterparty
• KLRA.US: Kailera, the obesity platform company built around Hengrui-origin assets outside Greater China
• 01177.HK: Sino Biopharm, a major China pharma comparator in innovation and commercialization breadth

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.